Skip to main content

Table 4 Life Table representation of cumulative incidence of adjusted therapeutic failure attributable to drug resistance among subjects treated with chloroquine (CQ) and CQ + sulfadoxine/pyrimethamine (SP) with msp-2 genotyping to distinguish recrudescence from reinfection

From: Combined chloroquine, sulfadoxine/pyrimethamine and primaquine against Plasmodium falciparum in Central Java, Indonesia

CQ CQ+SP
D N I W IR CIF D N I W IR CIF
0 26 0 0 0.00 0.00 0 87 0 0 0.00 0.00
2 26 0 0 0.00 0.00 2 87 0 2 0.00 0.00
4 26 0 0 0.00 0.00 4 85 1 1 0.01 0.01
7 26 0 0 0.00 0.00 7 83 0 0 0.00 0.01
11 26 1 0 0.04 0.04 11 83 0 0 0.00 0.01
14 25 1 1 0.04 0.08 14 83 0 0 0.00 0.01
18 23 1 1 0.04 0.12 18 83 0 2 0.00 0.01
21 21 1 2 0.05 0.16 21 81 0 1 0.00 0.01
28 18 3 0 0.17 0.30 28 80 0 2 0.00 0.01
  1. N = sample at risk of therapeutic failure at start of interval
  2. i = the number of cases of therapeutic failure during the interval
  3. w = the number of subjects withdrawn from the test during the interval due to exclusion from analysis, loss to follow-up after latest blood smear, intercurrent infection with another plasmodia species, or reinfection by different genotype P. falciparum or relapse/reinfection by P. vivax based on day of recurrent parasitemia CQ +DCQ concentrations
  4. IR = risk of therapeutic failure in the interval, calculated as i/(N-w/2)
  5. CIF = cumulative incidence of therapeutic failure, calculated as 1-[(1-IRn)(1-CIFn-1)], where IRn is the IR in the current interval and CIFn-1 is the cumulative incidence up to the previous interval
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us